Observational Study of Melanoma Patients Treated with IMLYGIC®

• Research type

  Research Study

• Full title

  A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® (Talimogene Laherparepvec) in Clinical Practice to Characterize the Risk of Herpetic Infection Among Patients, Close Contacts, and Health Care Providers; and Long-term Safety in Treated Patients

• IRAS ID

  249337

• Contact name

  Miranda Payne

• Contact email

  miranda.payne@ouh.nhs.uk

• Sponsor organisation

  Amgen Ltd

• Duration of Study in the UK

  5 years, 0 months, 1 days

• Research summary

  This postmarketing study will follow melanoma patients for up to
  5 years after the first IMLYGIC dose in clinical practice. There is no experimental
  intervention, and the study population will receive standard-of-care treatment as
  determined by their treating physician.

• REC name

  West Midlands - Black Country Research Ethics Committee

• REC reference

  18/WM/0304

• Date of REC Opinion

  29 Nov 2018

• REC opinion

  Further Information Favourable Opinion